{
    "id": 32737,
    "fullName": "CBL Y371del",
    "impact": "deletion",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "CBL Y371del results in the deletion of one amino acid in the linker region of the Cbl protein at amino acid 371 (UniProt.org). Y371del results in decreased apoptosis, increased cell cycle progression, and transformation of cultured cells in the presence of FLT3 (PMID: 20622007, PMID: 31943762), and therefore is predicted to result in a loss of Cbl protein function.",
            "references": [
                {
                    "id": 3307,
                    "pubMedId": 20622007,
                    "title": "Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20622007"
                },
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 867,
        "geneSymbol": "CBL",
        "terms": [
            "CBL",
            "C-CBL",
            "CBL2",
            "FRA11B",
            "NSLL",
            "RNF55"
        ]
    },
    "variant": "Y371del",
    "createDate": "03/10/2020",
    "updateDate": "03/10/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20878,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20887,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 9494,
                "therapyName": "Midostaurin + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20881,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35367,
            "profileName": "CBL Y371del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35376,
            "profileName": "CBL Y371del FLT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}